The stories about Pharmos and dexanabinol in relation to TBI is worth a read. Although they ultimately failed as could Neuren, the potential upside is enormous.
Think that current trials must be based around dexanabinol trials.
If Neuren is on a winner and has orphan drug status for some of its products then its current market cap will become nothing more than a joke.
Did say if!
The stories about Pharmos and dexanabinol in relation to TBI is...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.130(0.85%) |
Mkt cap ! $1.944B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.47 | $15.07 | $6.450M | 422.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1938 | $15.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.29 | 54 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |